Sign In
Buy PRTA
$8.92
-0.270 (-2.94%)
At Close: Jun 03, 2026
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 01'st Oct 2021
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein d
Prothena Announces Executive Appointments
04:05pm, Friday, 01'st Oct 2021
Expanded roles support the continued transition to a fully integrated biotechnology company focused on rare peripheral amyloid and neurodegenerative diseases Expanded roles support the continued trans
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
01:00pm, Thursday, 23'rd Sep 2021
VRTX vs. PRTA: Which Stock Is the Better Value Option?
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
09:13am, Saturday, 18'th Sep 2021
Promising drug candidates could lead to a best-in-class Alzheimer's treatment.
Here's Why Prothena (PRTA) is a Great Momentum Stock to Buy
01:24pm, Thursday, 09'th Sep 2021
Does Prothena (PRTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 03'rd Sep 2021
DUBLIN, Ireland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein
Prothena to Participate in Upcoming September Healthcare Conferences
04:05pm, Wednesday, 01'st Sep 2021
DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysre
Prothena CEO breaks down the biotech firm's clinical trial timeline for therapeutics
07:41pm, Tuesday, 24'th Aug 2021
Gene Kinney, the president and CEO of Prothena, explained on Tuesday's "Mad Money" where the biotechnology company's therapeutics stand across the development timeline.
Here is Why Prothena (PRTA) is Up More Than 155% in Three Months
01:09pm, Friday, 13'th Aug 2021
Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.
Prothena (PRTA) Q2 Earnings Top Estimates
07:01pm, Thursday, 05'th Aug 2021
Prothena (PRTA) delivered earnings and revenue surprises of 1.75% and -0.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Prothena Corp Q2 Earnings
04:30pm, Thursday, 05'th Aug 2021
Shares of Prothena Corp (NASDAQ:PRTA) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 187.88% year over year to $0.58, which beat the e
Prothena to Report Second Quarter 2021 Financial Results on August 5th
04:05pm, Thursday, 29'th Jul 2021
DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein d
Why Is Novo Nordisk Buying a Rare-Disease Candidate?
09:31am, Saturday, 24'th Jul 2021
The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.
Prothena: Underrated Player In Alzheimer's And Parkinson's Close To Securing First Drug Approval
08:07am, Saturday, 24'th Jul 2021
Prothena is a $2.25bn market cap biotech with a unique, epitope targeting approach to drug development. The company has resurrected its AL Amyloidosis drug Birtamimab and has a pivotal trial ongoing i
Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks
07:37am, Saturday, 17'th Jul 2021
Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.
